AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18708688 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric placebo (PL; n=20, 12 males, 8 females)
Number of subjects: 42
Study 18708688 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance-exercise training (RET)
Number of subjects: 42
Study 16582524 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam intramuscularly (Group M)
Number of subjects: 40
Study 16582524 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam intranasally (Group N)
Number of subjects: 40
Study 14514369 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard large trauma craniotomy (SLTC)
Number of subjects: 230
Study 14514369 — intervention group
Group type: COMPARATOR
Intervention: Routine craniotomy (RC)
Number of subjects: 230
Study 11427833 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia and sedation with propofol/alfentanil (Group I)
Number of subjects: 150
Study 11427833 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion with propofol/alfentanil (Group II)
Number of subjects: 150
Study 11427833 — intervention group
Group type: COMPARATOR
Intervention: Nurse-administered midazolam/meperidine (Group III)
Number of subjects: 150
Study 9566014 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic dental anesthesia (EDA)
Number of subjects: 32
Study 9566014 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic injection (LA)
Number of subjects: 32
Study 8067483 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment
Number of subjects: 40
Study 8067483 — intervention group
Group type: COMPARATOR
Intervention: Clinical management
Number of subjects: 40
Study 3142349 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin estolate (500 mg)
Number of subjects: 12
Study 3142349 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin ethylsuccinate (600 mg)
Number of subjects: 12
Study 3142349 — intervention group
Group type: EXPERIMENTAL
Intervention: Both erythromycin esters
Number of subjects: 12
Study 3142349 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin estolate
Number of subjects: 12
Study 3142349 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin ethylsuccinate
Number of subjects: 12
Study 4156289 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 20
Study 4156289 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 20
Study 28291587 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (D4)
Number of subjects: 6
Study 28291587 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (D5)
Number of subjects: 6
Study 28291587 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine (D2)
Number of subjects: 6
Study 28291587 — intervention group
Group type: COMPARATOR
Intervention: Acepromazine
Number of subjects: 6
Study 28291587 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (D3, D4, D5)
Number of subjects: 6
Study 25279807 — intervention group
Group type: EXPERIMENTAL
Intervention: QAM dosing of extended-release hydromorphone
Number of subjects: 15
Study 25279807 — intervention group
Group type: EXPERIMENTAL
Intervention: QPM dosing of extended-release hydromorphone
Number of subjects: 15
Study 23102797 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol 800 mcg
Number of subjects: 90
Study 23102797 — intervention group
Group type: COMPARATOR
Intervention: Buccal misoprostol 800 mcg
Number of subjects: 90
Study 21903473 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy (bolus and infusional fluorouracil plus leucovorin, followed by oxaliplatin and irinotecan)
Number of subjects: 410
Study 21903473 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy (FOLFOX6 followed by FOLFIRI)
Number of subjects: 410
Study 21903473 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy
Number of subjects: 410
Study 18691696 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer prototype
Number of subjects: 60
Study 18691696 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced fidelity prototypes
Number of subjects: 60
Study 18691696 — intervention group
Group type: EXPERIMENTAL
Intervention: More attractive mobile phone
Number of subjects: 60
Study 18691696 — intervention group
Group type: COMPARATOR
Intervention: Less appealing mobile phone
Number of subjects: 60
Study 16352689 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone (RSG; 8 mg/d; n = 13)
Number of subjects: 26
Study 15484307 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious sedation with i.v. midazolam (Mi-group, 52 pts)
Number of subjects: 226
Study 15484307 — intervention group
Group type: COMPARATOR
Intervention: Throat anaesthesia only (Co-group, 62 pts)
Number of subjects: 226
Study 15484307 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a relative during the procedure (Re-group, 58 pts)
Number of subjects: 226
Study 15484307 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional information with a videotape (Vi-group, 54 pts)
Number of subjects: 226
Study 11737035 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheezing children in Sweden
Number of subjects: 275
Study 11737035 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheezing children in Estonia
Number of subjects: 275
Study 11737035 — intervention group
Group type: COMPARATOR
Intervention: Domestic crowding
Number of subjects: 275
Study 11737035 — intervention group
Group type: COMPARATOR
Intervention: Mean baseline FEV1
Number of subjects: 275
Study 9433630 — intervention group
Group type: EXPERIMENTAL
Intervention: Model‐heterogeneity test
Number of subjects: 0
Study 9433630 — intervention group
Group type: COMPARATOR
Intervention: Admixture test
Number of subjects: 0
Study 31283521 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin desensitization combined with long-term Aspirin therapy
Number of subjects: 6
Study 31283521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29425912 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prophylaxis antibiotics
Number of subjects: 26
Study 29425912 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics for urinary tract infection treatment
Number of subjects: 26
Study 29425912 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent self-catheterisation
Number of subjects: 26
Study 27168265 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week (following 80 mg at week 0)
Number of subjects: 72
Study 27168265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 27168265 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (hfPGA 0/1 achieved)
Number of subjects: 72
Study 27168265 — intervention group
Group type: COMPARATOR
Intervention: Placebo (hfPGA 0/1 not achieved)
Number of subjects: 72
Study 27168265 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (with psoriatic arthritis history)
Number of subjects: 72
Study 27168265 — intervention group
Group type: COMPARATOR
Intervention: Placebo (without psoriatic arthritis history)
Number of subjects: 72
Study 27168265 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (BMI <30.28 kg/m2)
Number of subjects: 72
Study 27168265 — intervention group
Group type: COMPARATOR
Intervention: Placebo (BMI ≥30.28 kg/m2)
Number of subjects: 72
Study 24993605 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone plus standard care
Number of subjects: 0
Study 24993605 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 0
Study 21565436 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity human simulators (HFS)
Number of subjects: 44
Study 21565436 — intervention group
Group type: COMPARATOR
Intervention: Standardized patients (SP)
Number of subjects: 44
Study 21565436 — intervention group
Group type: COMPARATOR
Intervention: Community volunteers (CV)
Number of subjects: 44
Study 19855325 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional curvilinear movement arcs
Number of subjects: 14
Study 19855325 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidirectional exercises
Number of subjects: 14
Study 16960776 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated IFN-alpha 2a and ribavirin
Number of subjects: 265
Study 15229059 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg/day)
Number of subjects: 42
Study 15229059 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (8 mg/day)
Number of subjects: 42
Study 15229059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 11554887 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation with reduced off time to < or = 1.1 min
Number of subjects: 154
Study 11554887 — intervention group
Group type: COMPARATOR
Intervention: Standard on/off cycle of 30 s on and 5 min off
Number of subjects: 154
Study 9592991 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated protein C resistance (APCR)
Number of subjects: 65
Study 9592991 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor V Leiden
Number of subjects: 65
Study 9592991 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotype APCR
Number of subjects: 65
Study 7512433 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 20 mg
Number of subjects: 8
Study 7512433 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 125 mg
Number of subjects: 8
Study 7512433 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 8
Study 3139179 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg twice daily
Number of subjects: 135
Study 3139179 — intervention group
Group type: COMPARATOR
Intervention: Wedge mastectomy plus excision of symptomatic axillary lymph nodes
Number of subjects: 135
Study 3139179 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 135
Study 3139179 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 135
Study 30566211 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based tele-rehabilitation (TR)
Number of subjects: 0
Study 30566211 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiac rehabilitation (CR)
Number of subjects: 0
Study 27126710 — intervention group
Group type: EXPERIMENTAL
Intervention: fiber, fish oil and carotenoid-enriched tube feed formula
Number of subjects: 51
Study 25195590 — intervention group
Group type: EXPERIMENTAL
Intervention: Every 2 weeks cetuximab (500 mg/m²)
Number of subjects: 311
Study 25195590 — intervention group
Group type: COMPARATOR
Intervention: Weekly cetuximab (250 mg/m²)
Number of subjects: 311
Study 23281805 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (200 mg/m2, day 1) plus carboplatin (AUC 6 mg/mL/min, day 1) every 3 weeks (Arm A)
Number of subjects: 50
Study 23281805 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (1000 mg/m2, days 1 and 8) plus carboplatin (AUC 5 mg/mL/min, day 1) every 3 weeks (Arm B)
Number of subjects: 50
Study 21668751 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ketamine infusion (2 µg/kg/min)
Number of subjects: 30
Study 21668751 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ketamine infusion
Number of subjects: 30
Study 21668751 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study 18267006 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon gamma (1 x 106 IU recombinant human IFN gamma intramuscularly, daily for one month and then three times per week up to 6 months)
Number of subjects: 32
Study 18267006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 18267006 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon gamma
Number of subjects: 32
Study 17087052 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)-rich fish oil-fortified drink (0.60 g EPA + 0.26 g docosahexaenoic acid/d) for 12 weeks
Number of subjects: 151
Study 17087052 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 151
Study 15531765 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease Management (DM) program
Number of subjects: 1069
Study 11892888 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg of melatonin
Number of subjects: 53
Study 11892888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 9412917 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation music
Number of subjects: 59
Study 9412917 — intervention group
Group type: COMPARATOR
Intervention: No music (control)
Number of subjects: 59
Study 8030430 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine for 4 weeks
Number of subjects: 0
Study 8030430 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 0
Study 2446877 — intervention group
Group type: EXPERIMENTAL
Intervention: iloprost
Number of subjects: 24
Study 2446877 — intervention group
Group type: COMPARATOR
Intervention: hydroxy-ethyl starch (HES)
Number of subjects: 24
Study 31452471 — intervention group
Group type: EXPERIMENTAL
Intervention: PROPER intervention - structured and biannually repeated multidisciplinary medication review
Number of subjects: 0
Study 31740863 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Mobilisation with Arm Movement along with neurodynamics and manual traction
Number of subjects: 31
Study 31740863 — intervention group
Group type: COMPARATOR
Intervention: Neurodynamics and manual traction
Number of subjects: 31
Study 28329785 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + Beet Root Juice (BRJ)
Number of subjects: 26
Study 28329785 — intervention group
Group type: COMPARATOR
Intervention: Exercise + Placebo
Number of subjects: 26
Study 25864872 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Lidocaine with 1:100,000 epinephrine using the ICPAT
Number of subjects: 40
Study 25864872 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sterile saline using the ICPAT
Number of subjects: 40
Study 23167603 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (RIF)
Number of subjects: 171
Study 21801494 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.80 FiO(2)
Number of subjects: 24
Study 21801494 — intervention group
Group type: COMPARATOR
Intervention: 0.30 FiO(2)
Number of subjects: 24
Study 19335686 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tacrolimus
Number of subjects: 3
Study 19335686 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical betamethasone
Number of subjects: 3
Study 19335686 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc pyrithione shampoo
Number of subjects: 3
Study 16684385 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplements for 5 days a week
Number of subjects: 415
Study 16684385 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly supplements
Number of subjects: 415
Study 16684385 — intervention group
Group type: COMPARATOR
Intervention: No supplements (control group)
Number of subjects: 415
Study 15673180 — intervention group
Group type: EXPERIMENTAL
Intervention: Symmetrized faces
Number of subjects: 0
Study 15673180 — intervention group
Group type: EXPERIMENTAL
Intervention: Smooth motion
Number of subjects: 0
Study 15673180 — intervention group
Group type: COMPARATOR
Intervention: Two control motions
Number of subjects: 0
Study 15673180 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory tasks with symmetric orientation effects
Number of subjects: 0
Study 11958389 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human bFGF administered weekly by intravenous infusions of 2 microg/kg for 6 weeks (total dose 12 microg/kg)
Number of subjects: 24
Study 11958389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9042989 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose 20 g t.d.s. for 15 days
Number of subjects: 14
Study 9042989 — intervention group
Group type: COMPARATOR
Intervention: Lactose 20 g t.d.s. as placebo
Number of subjects: 14
Study 7706699 — intervention group
Group type: EXPERIMENTAL
Intervention: 50mg losartan
Number of subjects: 135
Study 7706699 — intervention group
Group type: COMPARATOR
Intervention: 20mg lisinopril
Number of subjects: 135
Study 7706699 — intervention group
Group type: COMPARATOR
Intervention: 25mg hydrochlorothiazide
Number of subjects: 135
Study 3373408 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 79
Study 3373408 — intervention group
Group type: COMPARATOR
Intervention: Griseofulvin
Number of subjects: 79
Study 3373408 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 79
Study 31365829 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib plus sildenafil
Number of subjects: 273
Study 31365829 — intervention group
Group type: COMPARATOR
Intervention: Nintedanib alone
Number of subjects: 273
Study 27834479 — intervention group
Group type: EXPERIMENTAL
Intervention: 26F resectoscope requiring cervical dilatation (group A)
Number of subjects: 80
Study 27834479 — intervention group
Group type: COMPARATOR
Intervention: 5-mm hysteroscope requiring vaginoscopic approach (group B)
Number of subjects: 80
Study 25555797 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl (54 μg per spray, mean total dose 734 μg, duration of use 3.5 h)
Number of subjects: 32
Study 25555797 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl
Number of subjects: 32
Study 24740462 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 79
Study 24740462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 23132474 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg intravenously 1 hour prior to subarachnoid block
Number of subjects: 80
Study 23132474 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo) 2 ml intravenously 1 hour prior to subarachnoid block
Number of subjects: 80
Study 18501499 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsatellite analysis (MA) of voided-urine samples
Number of subjects: 228
Study 17697450 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS hydromorphone in the treatment of chronic low back pain (CLBP)
Number of subjects: 1736
Study 17697450 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS hydromorphone in the treatment of pain associated with chronic osteoarthritis (OA)
Number of subjects: 1736
Study 17697450 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapping algorithm developed in the MOS study
Number of subjects: 1736
Study 15138569 — intervention group
Group type: EXPERIMENTAL
Intervention: 13‐cRA at a dose of 0.5 mg/kg per day per os
Number of subjects: 267
Study 15138569 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 267
Study 14746165 — intervention group
Group type: EXPERIMENTAL
Intervention: latanoprost 0.005%
Number of subjects: 71
Study 14746165 — intervention group
Group type: COMPARATOR
Intervention: timolol-pilocarpine
Number of subjects: 71
Study 9690954 — intervention group
Group type: EXPERIMENTAL
Intervention: Tucaresol 200 mg after overnight fast
Number of subjects: 18
Study 9690954 — intervention group
Group type: COMPARATOR
Intervention: Tucaresol 200 mg after ingestion of a standard breakfast
Number of subjects: 18
Study 9690954 — intervention group
Group type: EXPERIMENTAL
Intervention: Tucaresol 200 mg in females
Number of subjects: 18
Study 9690954 — intervention group
Group type: COMPARATOR
Intervention: Tucaresol 200 mg in males
Number of subjects: 18
Study 7659481 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine (DTaP)
Number of subjects: 0
Study 7659481 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-cell pertussis vaccine (DTP)
Number of subjects: 0
Study 7659481 — intervention group
Group type: COMPARATOR
Intervention: Whole-cell pertussis vaccine (WCL)
Number of subjects: 0
Study 2568785 — intervention group
Group type: COMPARATOR
Intervention: Iotrolan 240 mg I/ml
Number of subjects: 100
Study 2568785 — intervention group
Group type: COMPARATOR
Intervention: Iotrolan 300 mg I/ml
Number of subjects: 100
Study 2568785 — intervention group
Group type: COMPARATOR
Intervention: Iohexol 240 mg I/ml
Number of subjects: 100
Study 2568785 — intervention group
Group type: COMPARATOR
Intervention: Iohexol 300 mg I/ml
Number of subjects: 100
Study 409803 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam added to treatment
Number of subjects: 0
Study 409803 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 0
Study 409803 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam with phenobarbitone
Number of subjects: 0
Study 31880966 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m2 plus bevacizumab 15 mg/kg
Number of subjects: 599
Study 31880966 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab 15 mg/kg
Number of subjects: 599
Study 30934284 — intervention group
Group type: EXPERIMENTAL
Intervention: Entropy-based randomization method for bipartite rating networks
Number of subjects: 0
Study 30934284 — intervention group
Group type: EXPERIMENTAL
Intervention: Louvain community detection on the obtained network
Number of subjects: 0
Study 30934284 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of the method to categorical bipartite networks
Number of subjects: 0
Study 28981579 — intervention group
Group type: EXPERIMENTAL
Intervention: Group AWS-FOB (Pentax Airway Scope)
Number of subjects: 90
Study 28981579 — intervention group
Group type: COMPARATOR
Intervention: Group OVA-FOB (Ovassapian airway)
Number of subjects: 90
Study 25084742 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole mucoadhesive buccal tablet (MBT)
Number of subjects: 104
Study 25084742 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral amphotericin B suspensions
Number of subjects: 104
Study 23535839 — intervention group
Group type: EXPERIMENTAL
Intervention: Four cycles of standard FEC (fluorouracil, epirubicin, cyclophosphamide) followed by four cycles of docetaxel
Number of subjects: 3596
Study 23535839 — intervention group
Group type: COMPARATOR
Intervention: Eight cycles of anthracycline-based chemotherapy
Number of subjects: 3596
Study 21707626 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatekeeper Suicide-Awareness Program
Number of subjects: 195
Study 21707626 — intervention group
Group type: COMPARATOR
Intervention: Regular monthly continuing education class (Control)
Number of subjects: 195
Study 20303910 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 56
Study 20303910 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 56